mXELOXIRI Combined With Molecular Targeted Drug in mCRC — TRICAP  

Unresectable Metastatic Colorectal Cancer Clinical Trial

Official title: mXELOXIRI Combined With Molecular Targeted Drug as First-line Therapy in Patients With Initially Unresectable Metastatic Colorectal Cancer: A Phase II, Single-arm, Prospective Clinical Study

Status Recruiting

Clinical Trial Summary

The objective is to evaluate the efficacy and safety of modified XELOXIRI combined with molecular targeted drug as first-line therapy in patients with metastatic colorectal cancer (mCRC)

Clinical Trial Description

It is an investigator-initiated, single institution, prospective, single-arm clinical study to evaluate the efficacy and safety of modified XELOXIRI combined with molecular targeted drug as first-line therapy in patients with unresectable mCRC. Eligible patients will receive 8 cycles of mXELOXIRI with cetuximab or bevacizumab and then the maintenance therapy until disease progression (PD) or unacceptable toxicity, whichever occurs first. Study evaluation time is defined as up to 16 weeks after the first dosing of the last patient. ;

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Unresectable Metastatic Colorectal Cancer

• NCT number: NCT04160416
• Study type: Interventional
• Source: First Affiliated Hospital of Zhejiang University
• Contact: Jiang F Weiqin, M.D
• Phone: +86 15068117618
• Email: 1312028@zju.edu.cn
• Status: Recruiting
• Phase: Phase 2
• Start date: July 1, 2019
• Completion date: January 1, 2022